RLM.L Regulatory News (RLM)

1 May 2008 10:06

PuriCore Plc01 May 2008 Director's Dealings PuriCore Director Acquires Shares in the Company MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 1 May 2008-PuriCore (LSE: PURI), thelife sciences company focused on the control of infectious pathogens with itsnovel, safe antimicrobial technology, today announces that on 30 April 2008 thefollowing Director purchased shares in the Company, as set out below: Name Number of shares Purchase Price of Total number of % of issued share purchased shares shares held capital Greg Bosch 50,000 25.86p 83,433 0.05 Enquiries: Ben Brewerton Greg Bosch, CEOSusan Quigley Keith A. Goldan, CFOFinancial Dynamics PuriCore+44 (0) 20 7831 3113 +1 484 321 2700 About PuriCore PuriCore plc (LSE: PURI) is a life sciences company focused on developing andcommercialising proprietary products that safely, effectively, and naturallykill contagious pathogens. PuriCore's technology provides a solution to a broadrange of markets that depend upon controlling contamination, including foodsafety in retail and foodservice, medical device disinfection, wound therapy,and hospitality. The Company's proprietary technology mimics the human body'sproduction of the natural antimicrobial hypochlorous acid, which is highlyeffective in killing bacteria, viruses, and fungal spores. Deployinghypochlorous acid solutions as soaks, sprays, mists, and in other forms,PuriCore's technology is designed to limit the spread of infectious disease,including major public health threats of M. tuberculosis, MRSA, E.coli,Norovirus, Avian Influenza, HIV, Polio Virus, Helicobater pylori, andLegionella. PuriCore is headquartered in Malvern, Pennsylvania, with offices inStafford, UK. To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release. This information is provided by RNS The company news service from the London Stock Exchange